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Abstract
Background: The prevalence of neonatal abstinence syndrome (NAS) is increasing globally resulting in an increased
incidence of adverse neonatal outcomes and health system costs. Evidence regarding the effectiveness of NAS
prevention and management strategies is very weak and further research initiatives are critically needed to support
meta-analysis and clinical practice guidelines. In NAS research, the choice of outcomes and the use of valid, responsive
and feasible measurement instruments are crucial. There is currently no consensus and evidence-based core outcome
set (COS) for NAS.
Methods/design: The development of the NAS-COS will include five stages led by an international Multidisciplinary
Steering Committee: (1) qualitative interviews with parents/families and a systematic review (SR) to identify items for
inclusion in a COS. The SR will also identify participants for the Delphi survey, (2) a three-round Delphi survey to gain
expert opinion on the importance of health outcomes influencing NAS management decisions, (3), a consensus
meeting to finalize the items and definitions with experts and COS users, (4) feasibility and pilot testing, development
of the COS and explanatory document and (5) implementation planning.
Discussion: Since standardized outcome measurement and reporting will improve NAS clinical research consistency,
efficacy and impact, this COS will reflect the minimum set of health outcomes which should be measured in trials
evaluating interventions for preventing or treating NAS.
Background
In the last decade, the “opioid epidemic” has seen a
dramatic increase in the prevalence of opioid use [1, 2]
driven primarily by prescription drugs and relatively
inexpensive heroin. Not surprisingly, pregnant women
have also been significantly impacted. In 2010, the use of
prescription opioids during pregnancy was estimated at
14 % in the US [3]. Due to their liposolubility and low
molecular weight, opioids pass through the placenta and
are transmitted to the fetus. The rise in opioid use dur-
ing pregnancy has caused a dramatic increase in the
number of infants affected by NAS [4]. Postnatal opioid
use in ventilated newborns and those undergoing
surgical procedures further contribute to the burden of
NAS. Nonopioid substances, including antidepressants,
sedative-hypnotics, alcohol and tobacco, can potentiate
the NAS development resulting in more severe expres-
sion [5–7]. Recent reports on NAS have declared a
global epidemic, with prevalence ranging from 2 to 6 per
1000 live births [10].
NAS is a multisystem disorder characterized by distur-
bances in the central and autonomic nervous systems,
the gastrointestinal tract and the respiratory system. If
left untreated, NAS can cause death resulting from
seizures, respiratory instability and/or fluid loss and may
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result in long-term visual or auditory impairments [8, 9].
The impact on the health system is considerable. The
Canadian Institute for Health Information reported that
in Ontario, newborns with NAS used an average of 23.4
hospital beds per day, up from 5.6 beds per day in
2003–2004. North American centers report consump-
tion up to 45 % of neonatal intensive care unit (NICU)
days for babies with NAS [10]. The true number of
opioid exposures during pregnancy is difficult to capture
as not all babies exposed will develop NAS and not all
women are screened for opioid use in pregnancy, nor do
they readily disclose this information [11]. Most import-
ant, while comprehensive global efforts are underway to
address the opioid epidemic in adults, the care for new-
borns with NAS urgently needs attention [12].
There is no clinical best practice for the prevention or
treatment of NAS. Reported management of NAS is
variable and primarily based on eminence (experience)-
based practices [12]. The efficacy of NAS management
has been linked to several clinical and genetic factors;
however, the evidence is very limited in view of the
scope of the problem. In 2013, the WHO graded all avail-
able evidence on managing infants withdrawing from sub-
stance exposure in utero as “very low.” In October 2015,
the US government passed the “Protecting Our Infants
Act” (S.799) [13] committing resources to address
research gaps, review existing practices and create a for-
mal NAS surveillance program. In Canada and around the
world, variability in measurement and reporting of NAS
outcomes presents great challenges for health care
providers, social workers, researchers, policy-makers and
the community. The lack of harmonized, evidence-
and consensus-based NAS health outcomes impedes
progress in NAS clinical care and research. In the ab-
sence of harmonized outcome selection and reporting,
site performance and research studies cannot be com-
pared, contrasted nor combined, leading to inefficient
research efforts [14]. There is an acute need for a
core outcome set (COS) which is a minimum set of
outcomes to be collected in clinical care and research
in this disease area.
Aim
The aim of this study is to develop a consensus-based
COS for NAS to be used in clinical practice and research.
Objectives
(1)Synthesize evidence on maternal, neonatal and
health care resource utilization outcomes into a
comprehensive list of candidate outcomes for the
COS
(2)Interpret and prioritize NAS outcomes identified in
the systematic review (SR) using parent interviews, a
Delphi survey and a consensus meeting to develop a
COS
(3)Disseminate the NAS-COS to key stakeholders
globally
Methods
This initiative has been registered with COMET (Core
Outcome Measures in Effectiveness Trials) and PROS-
PERO (International Prospective Register of Systematic
Reviews). We will use published recommendations for
the development of a specific NAS-COS [15, 16], which
in our case will include five stages as outlined in Fig. 1:
(1) a SR and parent interviews to identify items for in-
clusion in a COS, (2) a three-round Delphi survey to
gain expert opinion on the importance of health out-
comes on influencing NAS management, (3) a consensus
meeting to finalize the items and definitions, (4) pilot
testing and the development of the COS explanatory
document and (5) knowledge translation. Each of the
following five stages (Fig. 1) is described in detail below.
Stage 1
Systematic review
In 2010 Cochrane published two SRs assessing the
effectiveness and safety of using an opiate compared to a
sedative or nonpharmacological treatment for treatment
of NAS [17, 18]. These reviews, which focus on manage-
ment effectiveness in randomized or quasi-randomized
trials, are currently in the process of being updated. We
will identify outcomes reported in all NAS clinical
research, including observational studies and clinical
trials. To foster transparency and promote collaboration,
the SR has been prospectively registered with PROS-
PERO. A comprehensive, electronic search was designed
by a research librarian at the Hospital for Sick Children.
All available English abstracts will be screened by two
independent reviewers. Maternal and neonatal health
outcomes will be extracted from full-text articles.
Types of studies, interventions and participants
Studies including SRs, clinical practice guidelines,
randomized controlled trials, case-controlled trials,
uncontrolled trials, case reports and observational co-
hort studies in NAS will be included. Reports of all in-
terventions used to manage NAS will be analyzed.
Although opioid-related NAS produces dramatic effects
in neonates, other substances, including antidepressants,
sedative-hypnotics, alcohol and tobacco, can contribute
to the severity of NAS [5, 7]. For the purpose of this
review, studies including neonates exposed to opioids
(including methadone, oxycodone and other illicit and
prescription opioids) in utero or postnatally who are
diagnosed with NAS will be included. Separate consider-
ation will be given to (1) in utero exposure and (2)
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postnatal exposure as these are often very different
neonatal populations. Studies that do not describe NAS
health outcomes or studies in which the full-text is not
available in English will be excluded.
Search methods for identification of studies
The search strategy was developed with a librarian at the
Hospital for Sick Children (Additional file 1). This
search will be applied to the Web of Science, CINAHL,
Cochrane Central, EMBASE and MEDLINE and re-
ported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guideline [19].
Eligibility of studies
Two independent reviewers will screen the abstracts
resulting from all search strategies in EndNote X6. For
all relevant studies, full-text articles will be obtained.
Any disagreement in study eligibility criteria will be
resolved by the principal investigator (PI). Studies will be
excluded if they do not describe NAS health outcomes
or if the full-text is not available in a language mastered
by our team (English, French, Spanish or Dutch). Opioid-
related NAS is the most common and produces the most
dramatic withdrawal effects in neonates. Other sub-
stances including antidepressants, sedative-hypnotics,
alcohol and tobacco can contribute to the severity and
onset of the NAS symptoms [5, 7]. Only infants with a
NAS diagnosis following opioid exposure in utero or
postnatally will be included regardless of concomitant
substance exposure.
Assessment of methodological quality
For each study that is included, the methodological qual-
ity of the reported outcomes will be assessed. As there is
no synthesis of data for the reported health outcomes
planned, the overall methodological quality of the study
will not be evaluated. We will use six questions [20] to
assess the quality of outcome reporting:
1. Is the primary outcome clearly stated?
2. Is the primary outcome clearly defined so that
another researcher would be able to reproduce its
measurement? (e.g. time points, person measuring
Fig. 1 Project flow for the development of a core outcome set (COS) for neonatal abstinence syndrome NAS. NAS-COS development will include
separate considerations for NAS resulting from (1) antennal opioid exposure (in utero) and (2) postnatal (iatrogenic) opioid use
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outcome, measurement tools, location of outcome
measurement)
3. Are secondary outcomes clearly stated?
4. Are the secondary outcomes clearly defined?
5. Do the authors explain the use of the outcomes they
have selected?
6. Where applicable assess measurement tools. Were
methods used to enhance the quality of outcome
measurement? (e.g. training)
Data extraction, analysis and presentation
Data will be extracted independently by two reviewers.
Discrepancies between data collection will be resolved by
a senior reviewer. From each included study the following
data will be extracted where available: journal of publica-
tion, authors, author affiliation/contact details, year of
publication, study design, population (antenatal or postna-
tal exposure), type of exposure including duration of ex-
posure, maternal dose (if in utero exposure), neonatal
dose (if postnatal exposure), timing and dose at onset, in-
clusion and exclusion criteria, NAS intervention type,
control arm, the number of patients included in the study,
and inclusion and exclusion criteria. These data will be
presented in a descriptive table and all reported outcome
measures will be documented and the quality of outcome
reporting for each study will be assessed. Of the outcomes
selected for the COS, the validity of measurement instru-
ments will be assessed using the most recent COSMIN list
[21]. No formal sample size has been calculated for the
Delphi process. Approximately 150 participants from
around the world, identified through the SR and Steering
Committee will be invited to participate.
Data interpretation, validation and prioritization
In order to contextualize the outcomes identified by the
SR, we will engage with health care providers and
parents with real-world NAS experience. In order to
ensure that outcomes identified during the SR are rele-
vant and meaningful in both a research and clinical care
setting, we will integrate findings from parent interviews,
the Delphi survey and the consensus meeting with key
stakeholders into the final COS.
Identification of outcomes important to parents and
families
It is important that the outcomes collected in both
research and routine care are meaningful to the patients
and families receiving care. As the patients in this case
are neonates, parents and families will be provided with
the opportunity to contribute to selecting appropriate
outcomes for infants with NAS. As the COS will include
both maternal and neonatal health outcomes the in-
volvement of mothers of newborns with NAS is critical.
A purposive sample, minimum of four caregivers (parents,
foster parents, or legal guardians) will be selected at the
coauthors’ substance abuse treatment centers. Parents of
infants displaying symptoms of NAS will be asked if they
would like to participate and offered a $20 CAD gift card
to a local eatery. The aim will be to select a representative
sample accounting for ethnic, socioeconomic and demo-
graphic distribution which includes both birth and foster
parents/caregivers. Parents/caregivers will complete quali-
tative interviews via an open-ended approach where they
will be asked to describe their experiences with their in-
fant’s NAS treatment and the impact on their families.
These interviews will be completed at discharge so that
caregivers do not feel as though their decision to partici-
pate or their responses will affect their infants care. The
goal of these interviews will be to gather evidence of
important issues raised by parents, caregivers and families.
These semistructured, open-ended interviews will include a
topic guide to ensure that all identified health outcomes are
discussed and the importance of each outcome is assessed.
Ethics board approval for the qualitative interviews will be
obtained prospectively and informed consent will be
obtained. All interviews will be recorded and transcribed
verbatim. Qualitative analysis software will be used to iden-
tify themes in the recordings and to identify outcome
domains important to parents and families. These outcome
measures will be identified independently from the SR.
Stage 2
Identification of outcomes important to health care
providers
A three-round Delphi approach has been selected to
investigate the importance of NAS outcomes to neonatol-
ogists, obstetricians, midwives, substance abuse treatment
providers, primary care physicians, nurses, nurse practi-
tioners and social workers. The Delphi will be conducted
using secure Delphi Manager® software hosted at the
University of Liverpool and, with the exception of the
open-ended Delphi round 1, will be completed using
SurveyMonkey. The Delphi survey will be completed
anonymously in order to account for all participants’ opin-
ions, to avoid influence from other participants, and to
maintain confidentiality. Only the study team will have
access to the participant contact information.
Participants
A wide variety of stakeholders, including all correspond-
ing authors of studies included in the SR, will be invited
to participate via e-mail. The e-mail will outline the pro-
ject including the timelines. Additional international
experts in neonatology, nursing, obstetrics, social work
and opioid exposure in pregnancy may be consulted at
the discretion of the Steering Committee. For applicabil-
ity, the NAS-COS aim to be relevant for international
settings across a variety of domains. The number of
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participants who are invited will be recorded along with
demographic information including, years of experience,
country of practice and qualifications. All correspond-
ing authors identified in the SR and knowledge users
identified by the Steering Committee will be invited to
participate via e-mail. For applicability, the NAS-COS par-
ticipants will include future potential NAS-COS users; we
expect over 150 individuals to be invited. Response and
attrition rates will be reported. Although development of
COS generally includes patients in the Delphi survey [15],
the authors felt that engagement through interviews was
better suited to interpret outcomes from a family
perspective given the nature of the patients (newborns).
Participants will include NAS-COS users. Parent and
family involvement will be sought during focus groups.
Delphi round 1
Participants will be assigned a unique identification code
and will not be able to see the responses or identification
of any other participants. Individuals will be invited via
e-mail to participate in round 1 of the Delphi survey
where they will consent to being contacted for rounds 2
and 3. The number of respondents who complete all
rounds will be recorded with response and attrition rates
being calculated and reported. Participants will be pro-
vided with study information, including institutional
approvals and contact information for questions. Prior
to distribution, the Delphi survey will be approved by
the Quality Improvement Team at the Hospital for Sick
Children. Previous COS developers have confirmed that
the National Research Ethics Committee does not
require Research Ethics Board approval for Delphi sur-
veys involving clinicians [20].
The first question will ask if participants are inter-
ested in the development of a COS for NAS. If they
agree, the remaining survey questions will be popu-
lated. The first round of the Delphi survey will collect
demographic information on the participants and will
present the study rationale. Unidentified demographic
information will include: number of years of practice,
location of practice, and clinical role (e.g. nurse,
neonatologist, obstetrician, researcher, pharmacist,
etc.). Round 1 will be open for 4 weeks and reminder
e-mails will be sent weekly to those invited. The
survey will be presented in an online format and will
be piloted within the Steering Committee prior to
distribution to assess clarity prior to distribution. To
ensure outcomes identified by the SR are relevant to
a wide range of NAS health care providers, round 1
will be an open-ended question: “Thinking about your
clinical and research practice, please list up to 10
outcomes that you feel are important to inform NAS
diagnosis and management.” For each health outcome,
participants will be provided with a text box to
describe how they would measure this outcome. Any
type of outcome (laboratory test, questionnaire, etc.)
can be included [22].
Delphi round 2 (outcome prioritization)
Round 2 of the Delphi will also be provided in an
electronic format using Delphi Manager®. To ensure
that a comprehensive set of NAS health outcomes is
generated, health care providers will be asked to
prioritize outcomes collected from: (1) round 1 of the
Delphi survey, (2) the SR (published literature), and
(3) from parent interviews with each item including
the source of information (experts, literature, families).
Outcomes will be grouped under the appropriate
domains, according to OMERACT domains (Death, Life
Impact, Pathophysiological Manifestations and Resource
Use) [23, 24] presented in alphabetical order to avoid the
appearance of a hierarchy. Participants will be asked
“What is the importance of this health outcome in
influencing your treatment of NAS?” The outcome
rating scale will range from 1 to 9,where 1 to 3 are
labeled “Not important for inclusion in the NAS-
COS,” 4 to 6 are labeled “Important but not critical
for inclusion in the NAS-COS” and 7 to 9 are labeled
“Critical for inclusion into the NAS-COS” [24]. Par-
ticipants will also be asked how they would measure
each presented outcome. This initiative has been
registered with COMET and PROSPERO [25]. Follow-
ing the importance rating of items identified from the
SR, an option to add in additional health outcomes
which they currently view as influencing care will be
provided in an open-text format.
Delphi round 3 (item reduction)
Participants will be presented with the results (mean,
median and range) for the top-scoring items from round
2. They will then be asked for each outcome if they feel
that this outcome would influence their care and should
be included on a NAS-COS where 0 = never, 1 = some-
times and 2 = always. To ensure that each outcome is
completely reported, outcome items will also include
data collected regarding measurement tools. For ex-
ample, with regarding the item #1 Neonatal Abstinence
Severity Score, your preferred measurement tool is (a)
Modified Finnegan score, (b) Lipsitz Neonatal Drug-
withdrawal scoring system, (c) Neonatal Withdrawal In-
ventory, (d) Neonatal Narcotic Withdrawal Index and
(e) any other scoring systems identified during the SR.
For each scale used in practice, participants will be asked
to report (1) how frequently infants are scored; (2) what
is the cut-off points for initiating pharmacologic man-
agement? (3) who is responsible for completing the scor-
ing; and (4) how long the neonates remain in hospital
for observation.
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Stage 3
Consensus meeting
Through purposive sampling, approximately 20 participants
from diverse stakeholder groups, including physicians,
nurses, nurse practitioners, midwives, social workers,
researchers and parent representatives, will be invited to
participate in a face-to-face meeting with the Steering
Committee. Journal editors, industry representatives and
regulators will also be invited to attend. The purpose of the
consensus meeting is to finalize the COS and to define each
outcome and measurement tool. The consensus meeting
will be conducted via a Nominal Group Process [26]. The
results from the Delphi survey will be presented as well as
qualitative data from the parent interviews. Similar to other
COS development protocols [19], consensus will be deter-
mined if 70 % or more participants scored the item with an
importance of 7 to 9 and less than 15 % of participants
scored the item as 1 to 3. All included and excluded items
will be reviewed during this time.
Stage 4
Pilot testing
The Steering Committee and those invited to the
consensus meeting will be invited to pilot test the
COS. Experienced COS developers will be identified
through COMET and consulted on the overall NAS-
COS. The International Neonatal Consortium (INC)
is a public-private partnership involving global regula-
tors, members of the academic community, families,
foundations and industry representatives united in the
goal of fostering neonatal clinical research. Members
of INC will be invited to provide feedback on the
overall relevance of the NAS-COS for clinical and
research practice.
Development of the COS and explanatory document
The COS reporting guideline will include all health
outcomes and measurement procedures as determined
by the parent interviews, Delphi rounds and consen-
sus meeting. The explanatory document will contain
all of the background, rationale and justification for
each health outcome and will be developed concur-
rently with the COS reporting guideline. All Delphi
survey participants will be provided with the final
COS document and given the opportunity to provide
feedback on content, format, and usefulness. Details
regarding the reported measurement of each identi-
fied NAS health outcome will also be included to
foster harmonization of data collection. Examples of
good reporting will be provided in the explanation
document. The first drafts will be developed by the
project leaders and distributed to the Steering
Committee for comment and approval.
Stage 5
Knowledge translation
A central priority of this research is to increase aware-
ness regarding the importance of COS in the field of
NAS research and treatment. Active involvement of
partners will be achieved by bringing representatives
together from diverse international stakeholder groups
in the selection and prioritization of NAS health
outcomes and subsequent development of the COS.
Stakeholders will remain engaged throughout the evalu-
ation and implementation process, and be provided with
an active role in the strategic planning on actions to
amplify the impact of the NAS-COS.
Our audience includes:
1. Researchers and health care providers – to use the
NAS-COS in future clinical research (e.g. Canadian
Association of Pediatric Health Centers, American
Academy of Pediatrics, Canadian Pediatric Society,
The Society of Obstetricians and Gynecologists of
Canada)
2. Systematic reviewers – to use the NAS-COS to
identify important outcomes and promote the use of
NAS-COS in future research (e.g. Cochrane Child
Health, Cochrane Neonatology)
3. Funding agencies and journals – to encourage the
use of NAS-COS in future research (e.g. CIHR,
NIH, JAMA Pediatrics, Pediatrics)
4. Health care system – to use NAS-COS for routine
monitoring and plan quality improvement activities
(e.g. European Medicines Agency, Food and Drug
Administration, Health Canada)
Our integrated knowledge translation plan encom-
passes education, dissemination, and endorsement by
various key stakeholders as summarized in Table 1. Our
involvement of all corresponding authors and a wide
variety of knowledge users (neonatology, health policy,
perinatal addiction, pharmacology, midwifery, nursing
and social work) in the development of the COS will
maximize implementation by NAS research teams and
clinicians around the world. Additional funding will
be sought for a formal prospective evaluation of the
NAS-COS including a survey of users citing the use
of the NAS-COS 5 years post publication. This evalu-
ation will include a plan for quality improvement and
examination of implementation barriers such as a lack
of training or cost.
The methods for developing the NAS-COS are being
drafted for publication and will be written according to
the reporting guideline for studies developing a COS [4].
Registration and protocol publication will raise aware-
ness of the COS development, encourage collaboration,
provide expert resources and increase uptake. The NAS-
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COS will be published in a journal with a neonatology
focus and CROWN (CoRe Outcomes in WomeN’s health)
will be consulted. Journals which publish neonatology
research will be contacted to support NAS-COS imple-
mentation. Additional journals may be identified through
the SR. To foster transparency, the authors plan to publish
the results from the SR in the explanatory document that
focuses on the quality of outcome reporting and variability
in NAS. These data will be presented at international con-
ferences to foster dissemination globally.
Neonatal specialty groups, identified through INC will
be presented with the COS and asked to disseminate to
their members. As there are relatively few investigators
conducting NAS research, involving all corresponding
authors in the design of the COS will maximize imple-
mentation by NAS research teams around the world. A
formal evaluation of the COS will include a survey of
users citing the use of the NAS-COS 5 years post publi-
cation. This evaluation will include a plan for quality
improvement and evaluate implementation barriers such
as a lack of training or cost.
Discussion
According to the Canadian Pediatric Society (CPS) there
is no best practice for managing newborns with NAS in
Canada or in other parts of the world. As the health care
costs associated with NAS management are six times
the costs associated with non-NAS births [27], the
increasing number of NAS cases, locally occupying more
than 20 % of NICU days, is a worrisome resource
burden. Research done to establish treatment effective-
ness must select and report qualified, valid and feasible
health outcomes. In order to accelerate the discovery of
beneficial treatment strategies, reduce research waste
and optimize resource allocation, high-quality effective-
ness evidence must be generated and synthesized. Efforts
to improve the quantity and quality of NAS research
have been highlighted by the call to action of the US
Congress and NIH.
There is currently no published COS for NAS. This
paper describes the development of evidence and
consensus-based COS aims to improve the comparison of
future studies, improve research quality and harmonize
outcome selection/measurement. This review will provide
a current and transparent assessment of the NAS health
outcomes that will inform clinical practice and the design
of large multicenter comparative effectiveness trials. The
NAS-COS is a first step in facilitating high-quality
evidence that will ease the comparability between
studies and foster meta-analysis. The NAS-COS will
incorporate key stakeholder groups, including parents
and families to develop a meaningful and feasible set
of health outcomes. Through engaging health care
providers and families with real-world NAS experi-
ence to interpret and prioritize the NAS outcomes,
we will generate a meaningful and relevant COS to
inform the design of large, multicenter comparative
effectiveness trials, prospective SRs, and meta-analyses
with the goal of markedly improving care for this
highly vulnerable population.
Table 1 Neonatal abstinence syndrome core outcome set (NAS-COS) knowledge translation plan
Education • Our collaborators have committed to including the NAS-COS in the next edition of the Ontario NAS guidelines
and the Canadian Pediatric Society NAS Practice Point
• Methods for developing the NAS-COS will be reported in a separate publication which will be written according
to the reporting guideline for studies developing COS
• Registration and protocol publication will raise awareness of this COS development, encourage collaboration, and
provide expert resources and increase uptake
• Collaborative training initiatives within the Canadian Child Health Clinician Scientist Program and Women and
Babies Clinical Educators Network
Dissemination • The results from the systematic review (SR) will be published, focusing on the quality of outcome reporting and
variability in outcome selection/measurement
• The SR and COS findings will be disseminated through several large international organizations including: the
European Society of Pediatric Research, the European Society of Developmental Pharmacology, International
Neonatal Consortium, Perinatal Society of Australia, American Academy of Pediatrics, Canadian Neonatal Nurses
Association, American Pediatric Society, Neonatal Advisory Committee at the Food and Drug Administration, CPS
Fetus and Newborn Committee, and the Canadian Neonatal Network (CNN)
• The COS will be presented at international conferences to foster awareness globally. Funds are requested to
present this work at the Pediatric Academic Societies, American Academy of Pediatrics, and the European Society
for Pediatric Research annual meetings
Endorsement • The Steering Committee will use the NAS-COS to inform the design of our own planned clinical research
in this area
• Update the Canadian BORN and CNN databases
• Published in neonatology journals
• Prospective engagement with Core Outcome Measures in Effectiveness Trials (COMET)
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